Format

Send to

Choose Destination
J Alzheimers Dis. 2014;41(1):243-60. doi: 10.3233/JAD-132177.

Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer's disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Aβ₁₋₁₅ fused to toxin-derived carrier proteins.

Author information

1
Beijing Institute of Biotechnology, Beijing, China.
2
Beijing Institute of Biotechnology, Beijing, China Pharmaceutical College, Henan University, Kaifeng, China.
3
Beijing Institute of Biotechnology, Beijing, China Institute of Life Science and Biotechnology, Beijing Jiaotong University, Beijing, China.
4
Pharmaceutical College, Henan University, Kaifeng, China.
5
Institute of Life Science and Biotechnology, Beijing Jiaotong University, Beijing, China.

Abstract

Targeting on the amyloid-β (Aβ) is a promising immunotherapeutic strategy for Alzheimer's disease (AD). However, Aβ(1-15) sequence alone induces low antibody response and poor protection against AD. We describe here the immunological characterization and protective efficacy of several recombinant chimeric vaccines with hexavalent foldable Aβ(1-15) (6Aβ15) fused to PADRE or toxin-derived carrier proteins. Immunization with these chimeric antigens generated robust Th2 immune responses with high anti-Aβ42 antibody titers in different mice, which recognized neurotoxic Aβ42 oligomers, but did not stimulate Aβ42-specific T cell responses. These 6Aβ15 chimeric vaccines markedly reduced Aβ pathology and prevented development of behavioral deficits in immunized older AD mice. Importantly, toxin-derived carrier proteins as molecular adjuvants of chimeric vaccines could substantially boost immune responses and overcome Aβ- and old age-associated hypo-responsiveness, and elicit long-term Aβ-specific antibody response, which in turn inhibited Aβ-mediated pathology and improved acquisition and retention of spatial memory in immunized AD mice. These data indicate that toxin fragments as molecular adjuvants are promising new tools for the rational design and development of prototype chimeric vaccines for AD and this type of chimeric vaccine design has the added advantage of overcoming hypo-responsiveness in elderly AD patients with pre-existing memory Th cells from tetanus toxin.

KEYWORDS:

Alzheimer's disease; carrier protein; chimeric vaccines; immunotherapy; molecular adjuvant

PMID:
24625800
DOI:
10.3233/JAD-132177
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center